1. Home
  2. CPOP vs CVKD Comparison

CPOP vs CVKD Comparison

Compare CPOP & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pop Culture Group Co. Ltd

CPOP

Pop Culture Group Co. Ltd

N/A

Current Price

$3.39

Market Cap

2.9M

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

N/A

Current Price

$0.96

Market Cap

3.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CPOP
CVKD
Founded
2007
2022
Country
China
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.4M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
CPOP
CVKD
Price
$3.39
$0.96
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
17.1K
★ 142.0K
Earning Date
11-16-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.82
52 Week High
$6.71
$13.60

Technical Indicators

Market Signals
Indicator
CPOP
CVKD
Relative Strength Index (RSI) 52.01 42.56
Support Level $0.27 $0.83
Resistance Level $3.76 $1.12
Average True Range (ATR) 0.33 0.10
MACD -0.06 0.01
Stochastic Oscillator 40.59 38.62

Price Performance

Historical Comparison
CPOP
CVKD

About CPOP Pop Culture Group Co. Ltd

Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: